MindBio Therapeutics Enrolls 25th Participant into Landmark Take-Home Microdosing Depression Trial | Psychedelic Invest
Vancouver, British Columbia –TheNewswire –September 23, 2024–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),a leading biopharmaceutical company in psychiatric medicine development, is delighted to report